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Abstract
Background: Since it is impossible to sequence the complete CFTR gene routinely, clinical
laboratories must rely on test systems that screen for a panel of the most frequent mutations
causing disease in a high percentage of patients. Thus, in a cohort of 257 persons that were referred
to our laboratory for analysis of CF gene mutations, reverse line probe assays for the most
common CF mutations were performed. These techniques were evaluated as routine first-line
analyses of the CFTR gene status.
Methods: DNA from whole blood specimens was extracted and subjected to PCR amplification
of 9 exons and 6 introns of the CFTR gene. The resulting amplicons were hybridised to probes for
CF mutations and polymorphisms, immobilised on membranes supplied by Roche Molecular
Systems, Inc. and Innogenetics, Inc.. Denaturing gradient gel electrophoresis and sequencing of
suspicious fragments indicating mutations were done with CF exon and intron specific primers.
Results: Of the 257 persons tested over the last three years (referrals based on 1) clinical
symptoms typical for/indicative of CF, 2) indication for in vitro fertilisation, and 3) gene status
determination because of anticipated parenthood and partners or relatives affected by CF), the
reverse line blots detected heterozygote or homozygote mutations in the CFTR gene in 68 persons
(26%). Eighty-three percent of those affected were heterozygous (47 persons) or homozygous (10
persons) for the ∆F508 allele. The only other CF-alleles that we found with these tests were the
G542X allele (3 persons), the G551D allele (3 persons), the 3849+10kb C-T allele (2 persons) the
R117H allele (2 persons) and the 621+1G-T allele (1 person).
Of the fifteen IVS8-5T-polymorphisms detected in intron 8, seven (47%) were found in males
referred to us from IVF clinics. These seven 5T-alleles were all coupled with a heterozygous ∆F508
allele, they make up 35% of the males with fertility problems (20 men) referred to us.
Conclusions: In summary, the frequency of CF chromosomes in the cohort examined with these
tests was 26%, with the ∆F508 allele affecting 83% of the CF chromosomes. It is a substantial
improvement for routine CF diagnostics to have available a test system for 30 mutations plus the
polypyrimidine length variants in intron 8. Our results show that this test system allows a routine
first-line analyses of the CFTR gene status.
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Background
Diagnosis of hereditary human disease to date requires ar-
duous techniques and intense manual handling. When a
disorder is caused by mutations in a large gene and at mul-
tiple loci, the demands pose considerable challenges to
the testing laboratory. In some cases, the underlying mu-
tations can not be found at all, because it is impossible to
sequence complete genes routinely. Consequently, clini-
cal laboratories must rely on test systems that screen for a
panel of the most frequent mutations causing disease in a
high percentage of patients, in order to minimise the need
for further elaborate protocols.
Accordingly, for the diagnosis of mutations that lead to
cystic fibrosis, a panel of methods is needed, i.e. PCR-
based techniques, reverse blots, DGGE, sequencing a.s.o
[1]. The demand for improved tools for CF diagnostics is
substantial, because cystic fibrosis is among the most
common autosomal recessive diseases in the Caucasian
population. It affects 1:2000–1:3000 births each year and
results in pulmonary failure and death in most cases at
around the third decade of life [2]. The molecular defect
in CF was elucidated following the cloning of the cystic fi-
brosis transmembrane conductance regulator (CFTR)
gene [3]. So far, over 800 different mutations are recorded
that lie in introns and exons. Recently, association of
CFTR mutations with other diseases – such as congenital
bilateral absence of vasa deferentia (CBAVD) [4,5] dis-
seminated bronchiectasis [6], or allergic bronchopulmo-
nary aspergillosis [7] – have emerged. This is not
surprising considering the cellular heterogeneity of CFTR
expression and the multiple mutations in this gene [8–
10]. In the case of CBAVD a strong association between
the repeat number of a polypyrimidine tract in intron 8 of
the CF gene with the absence of the vas deferens was
found [11,12].
Our laboratory performs CF diagnostics for the north-
eastern part of Austria. In this area – including and sur-
rounding Vienna – reside approximately three million in-
dividuals. We have been using reverse line blot assays for
CF mutations that encompass up to 29 mutations, 3 pol-
ymorphisms, and 3 alleles of the intron 8 polypyrimidine
tract for a rapid first screening of patient samples (table 1)
complemented by DGGE and sequencing as indicated (ta-
ble 2). The test panel fared well in the ECCACF (European
Community Concerted Action for Cystic Fibrosis) Quality
Control Trial of 1997, 1998, 1999, 2000, and 2001.
The aim of this study was the exploration of the screening
procedure for CF mutations employed in our laboratory
as a first-line diagnostic instrument for Cystic Fibrosis.
Here, we report our experiences with various test systems
and the resultant CF mutations in persons from north-
eastern Austria, referred to our laboratory for CF diagnosis
since 1999.
Methods
Patients
In all, 135 men and 122 women were analysed. The male
group consisted of 64 children (< 1–18 yrs) and 71 adults
(mean age of 32 yrs, range 19–69). The group of females
included 56 children (< 1–18 yrs) and 66 adults (mean
age of 31 yrs, range 19–65). All probands (or their par-
Table 1: Exons and introns that are amplified with the line probe assay, and the mutations they encompass
Roche assay:
Amplicon Mutations
exon 4 R117H,621+1G → T
exon 7 R334W, R347P
exon 9 A455E, 5/7/9T polymorphism
exon 10 ∆1507, ∆F508. F508C, I507V, I506V polymorphism
exon 11 1717-1G → A, G542X, S549N, G551D, R553X, R560T
exon 20 W1282X
exon 21 N1303K
intron 19 3849+10kb C → T
Innogenetics assay:
exon 3 394delTT, G85E, E60X
exon/intron 4 621+1G-T, R117H
exon 7 1078delT, R347P, R334W
exon 13 2143delT, 2183AA-G, 2184delA
exon 19 R1162X, 3659delC
intron 5 711+5G-A
intron8/exon 9 A455E,, 5T,7T,9T
intron 14b 2789+5G-A
intron 19 3849+10kb C-TBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
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Table 2: Genotypes of patients with mutations, final results
Group 1) (patients with symptoms typical for/indicative of CF)
No.: Diagnosisa Sex Age Intron 8 16 mut. 29 mut.b seq.c DGGEd
12   × path. IRT, normal sweat test f 0 7T/9T DF508/3849+10kb C-T x
2 CF, substantiation f 0 9T/9T 621+1G-T/621+1G-T
3 CF, substantiation f 1 9T/9T DF508/DF508 x
4 CF, substantiation f 5 9T/9T DF508/DF508 x x x
5 CF, substantiation f 7 9T/9T DF508/G542X x x
6 CF, substantiation, rec. diarrhoe, pancreas 
insufficiency, pos. sweat test
f 8 9T/9T DF508/DF508 x
7 CF, substantiation f 12 9T/9T DF508/DF508 x
8 CF, substantiation f 13 9T/9T DF508/DF508 x
9 f 13 7T/9T DF508/WT
10 CF, substantiation f 16 9T/9T DF508/G542X
11 indicative linkage analysis f 22 7T/9T DF508/WT x
12 f 24 7T/9T DF508/WT x
13 bronchiectasis, bronchopulmonal infections 
since infancy
f 28 7T/9T DF508/3849+10kbC-T x
14 pos. sweat test f 28 9T/9T DF508/WT x
15 typical clinic, pos. sweat test f 31 7T/9T DF508/WT x x
16 f 32 7T/7T 3849+10kb C-T/WT
17 pulmonal course typical of CF f 32 7T/9T DF508/WT x x x
18 f 34 7T/7T G551D/WT x x
19 f 41 7T/7T DF508/WT
20 CF, substantiation f 56 7T/9T DF508/3849+10kb C-T x
21
22 CF, substantiation m 0 9T/9T DF508/DF508 x
23 m 1 7T/9T DF508/WT x
24 impaired lung function, intestinal complications m 3 7T/9T DF508/WT x x
25 CF, substantiation m 5 9T/9T DF508/DF508
26 m 12 7T/7T G551D/WT x x
27 CF, substantiation m 17 9T/9T DF508/DF508
28 m 18 7T/7T R117H/WT&1466delAATT/1466delAATT 1466delAATT x
29 pos sweat test m 20 7T/9T DF508/WT
30 CF, substantiation m 25 9T/9T DF508/DF508
31 . m 26 5T/9T DF508/WT
32 m 30 5T/9T DF508/WT
33 CF, substantiation m 31 7T/9T DF508/1248A-G x 1248 A/G x
34 2 × pos. sweat tests, bronchopul. infect., 
azoospermia, pancreatitis
m 31 9T/9T DF508/WT
35 CF, substantiation m 33 9T/9T DF508/DF508 x
36 m 33 7T/9T DF508/WT
37 m 33 7T/9T DF508/WT
38 m 38 7T/9T R117H/G542X
Group 2a) (Patients from IVF clinics)
No.: Diagnosis Sex Age Intron 8 16 mut. 29 mut.b seq.c DGGEd
39 m 24 7T/9T WT
40 m 25 9T/9T WT
41 m 28 5T/9T DF508/WT x
42 m 28 5T/9T DF508/WT
43 m 29 5T/9T DF508/WT x x x
44 m 30 7T/7T WT x
45 m 31 5T/9T DF508/WT x x x
46 m 31 7T/7T WT x
47 m 31 7T/9T WT x
48 m 33 7T/9T DF508/WT x
49 m 34 7T/7T WT x
50 m 34 9T/9T DF508/WT x
51 m 35 7T/9T G542X/WT
52 m 36 5T/9T DF508/WTBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
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ents, respectively) had given informed consent for genetic
analysis as required by the Austrian law. Patients and
probands referrals to our laboratory for CF mutation anal-
yses were based on
1) clinical symptoms typical for/indicative of CF,
2) indication for in vitro fertilisation (IVF – group 2a:
men, 2b: their spouses), and
3) gene status determination because of anticipated par-
enthood and partners or relatives affected by CF.
Of all 257 persons analysed for CF mutations, 105 were
examined for 16 mutations, 152 for 29 mutations, 31 in-
dividuals were tested further by DGGE of all exons and se-
quencing of suspicious fragments.
DNA studies
DNA was extracted routinely from blood using the
Kristal™ DNA extraction kit (Cambridge Molecular Tech-
nologies, Cambridge, England). The INNO-LiPa
CFTR17+Tn (INNOGENETICS, Ghent, Belgium) assay
was performed according to the recommendation of the
supplier.
For the evaluation of the Amplicor® Cystic Fibrosis kit
(Roche Molecular Systems, Alameda, CA, USA), the ex-
traction protocol included in the kit was tested, as well.
For this test, 100 µL blood was incubated 5 to 10 min with
1 ml "Specimen Wash Solution" as supplied in the test kit
in Eppendorf vials to lyse red blood cells. The solution
was centrifuged for 1 min at maximum speed in a micro-
fuge and the supernatant was discarded. The leucocyte
pellet was treated once more with "Specimen Wash Solu-
53 m 39 5T/9T DF508/WT x x
54 m 40 7T/7T WT
55 m 40 5T/9T DF508/WT x x x
56 m 44 9T/9T WT
57 m 45 7T/7T WT x
58 m 47 7T/7T WT
Group 3) (Patients with relatives having CF)
No.: Diagnosis Sex Age Intron 8 16 mut. 29 mut.b seq.c DGGEd
59 f 42 7T/7T 3849+10kb C-T/WT x
60 f 15 7T/9T DF508/WT x
61 f 20 7T/9T DF508/WT x
62 f 23 7T/9T DF508/WT x
63 f 25 7T/9T DF508/WT x x x
64 f 26 7T/9T DF508/WT
65 f 32 7T/9T DF508/WT x
66 f 40 7T/9T DF508/WT x x
67 f 65 9T/9T DF508/WT
68 f 30 7T/9T DF508/WT x
69 m 14 9T/9T DF508/WT x
70 m 16 7T/9T DF508/WT
71 m 25 7T/9T DF508/WT x x x
72 m 28 5T/9T DF508/WT x
73 m 32 7T/9T DF508/WT x x
74 m 45 7T/9T DF508/WT x x
75 m 48 7T/9T DF508/WT x
76 m 69 7T/9T DF508/WT
77 m 30 7T/9T G542X/WT x x
78 m 15 7T/7T G551D/WT x
Details for diagnoses, number of mutations analysed, methods used, and other specifics for individuals with found mutations within the three groups 
are shown. A complete documentation comprising all persons examined is available upon request. Asterisks denote samples that were tested addi-
tionally to the Roche assay. In two cases, mutations were found only by sequencing, these mutations are shown in the column "seq". Other than 
that, all mutations were found merely by the Roche assay. aThe diagnoses are shown for the individuals specified. In the cases, where no diagnosis 
are given, the referrals were based on clinical symptoms suspicious for CF. No special diagnosis is given for the group of patients from IVF clinics 
and probands with relatives having CF. bThe asterisk denotes individuals that were analysed for 29 mutations (see table 1). cFragments (one to five) 
were sequenced when the DGGE analysis d showed bands indicating heterozygosity.
Table 2: Genotypes of patients with mutations, final results (Continued)BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
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tion" as above. The final pellet was taken up in "Extraction
Reagent" and the subsequent steps were performed analo-
gous to Kristal kit-extracted DNA: Cell pellets or DNA
(minimum of 400 ng in a volume of 50 µL or less) were
incubated in 200 µL Extraction Reagent for 30 min at
100°C. Twenty-five µL of this solution were PCR-ampli-
fied with 25 µL of 16.5 mmol/L Magnesium Chloride so-
lution and 50 µL PCR "Mastermix" according to the
manufacturers specification. The resulting amplicons
were denatured immediately with "Denaturing Solution"
to inhibit the action of uracyl-N-glycosylase (Amperase)
present in the Mastermix. The panels with immobilised
probes for 16 CFTR mutations and some polymorphisms
were prehybridised for 10 min with "Hybridisation Buff-
er" (3× SSPE + 0.5% SDS). Then, 100 µL denatured ampli-
cons were hybridised to the probes for 20 min at 50°C in
hybridisation buffer. After a stringent wash for 12 min at
50°C with "Wash Buffer" (2× SSPE + 0.3% SDS) the pan-
els were incubated with Streptavidin-Horseradish-Peroxi-
dase-Conjugate. After further wash steps, addition of
substrate (hydrogen peroxide + tetramethylbenzidine)
produces a blue precipitate at the regions of hybridisation.
Individual bands can be identified by superimposing a
transparent foil with the identification codes imprinted.
DGGE analyses and sequencing
For the individuals specified in table 2), all exons were an-
alysed by DGGE according to Audrezet et al. [20]. Suspi-
cious fragments indicating mutations were sequenced on
a Licor 4000L sequencing machine.
Results
Patients
Patients and probands referrals to our laboratory for CF
mutation analyses were based on
1) clinical symptoms typical for/indicative of CF, (the
clinical symptoms that prompted analysis for CF gene sta-
tus comprised: prior positive tests for immune reactive
trypsinogen (IRT), positive sweat test (> 60 mmol chlo-
ride/L), lung disease (bronchiectasies), and others,
2) indication for in vitro fertilisation (IVF – group 2a:
men, 2b: their spouses), and
3) gene status determination because of anticipated par-
enthood and partners or relatives affected by CF.
The first group (symptomatic) was comprised of 83 male
(mean age: 29 yrs, range: 19–48 yrs) and 88 female pa-
tients (mean age: 31 yrs, range: 19–61 yrs) with 114 chil-
dren/adolescents (60 male, 54 female) from < 1 to 18 yrs,
the mean age of this group was 13.5 yrs. The clinical
symptoms for the individuals with mutations (where giv-
en) are shown in table 2), a complete list is available upon
request.
The group 2a) (IVF) referred to us from IVF clinics includ-
ed 20 men (mean age: 34 yrs, range 24–47 yrs), group 2b
(IVF) twelve of their spouses with a mean age of 30 yrs
(range: 22–36 yrs) and a presumable risk of being a CF
carrier equal to the population risk. Clinical symptoms in
men included CBAVD, atrophy of the testes, aplasy of the
ductus deferens, aplasy of the epidymes, and azoosper-
mia. The women in group 2b (all without clinical symp-
toms) were referred to CF analysis for gene status
determination in the context of in vitro fertilisation.
Group 3 (mean age: 29 yrs, range: 9–69 yrs) consisted of
26 men and 28 women. These persons wanted their gene
status to be determined, because either their children or
close relatives were afflicted by CF. The group included 17
couples and 12 individuals that wanted to be tested in the
context of planned parenthood.
Amplicor cystic fibrosis test
The Roche Amplicor CF mutation test strip was evaluated
by analysing in parallel 100 samples with a panel of tech-
niques established in our laboratory (Inno LiPa reverse
dot blot – first generation, DGGE, sequencing). For 27
persons in this cohort this included sequencing of one to
five exons. Besides various polymorphisms, only one
splice site and one frameshift mutation were found. Thus,
97% of all mutations in this cohort that we could find
routinely following our established protocols could be an-
alysed with the Roche Amplicor Cystic Fibrosis test.
The test is based on three major processes: Polymerase
chain reaction target amplification, hybridisation of the
amplified products to specific oligonucleotide probes,
and detection of the probe-bound amplified product by
colour formation.
DNA is extracted from minute amounts of patients blood
by lysis of the red blood cells and incubation in Extraction
Buffer at 100°C. This method is quick (45 min) and re-
sults in very good quality of DNA. Subsequently, the DNA
is PCR amplified with 8 pairs of biotinylated primers that
simultaneously amplify eight different regions of the
CFTR gene (Table 1 – amplified regions plus the muta-
tions they encompass). In addition to the analysis of 16
common mutations, the assay yields information about
the poly-T tract in intron 8 and polymorphisms at locus
F508. Single base exchanges at this locus could lead to a
lesser extent of hybridisation to the gene probes that dis-
tinguish between F508 and ∆F508. By comparison to the
hybridisation pattern at the polymorphic probes (see Fig.
1), misinterpretation can be excluded.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
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After the PCR, the amplicons are alkali denatured to form
single strands which then will hybridise to bound probes.
After stringent washes, a horseradish peroxidase-streptavi-
din complex binds to the biotin-labelled amplicons cap-
tured by the membrane bound probes via the streptavidin
moiety. This conjugate is reacted after further washing
steps with hydrogen-peroxide and TMB to form a colour
complex.
DNA studies
A total of 71 patients had CFTR mutations or the 5T allele
or both (table 2 – final results for all methods used), 19
patients were found to have two mutations, 49 to have
one mutation (not counting the 5T allele).
Among 114 children < 18 yrs in group 1), we found 9 pa-
tients to be homozygote for ∆F508, two compound heter-
ozygote for ∆F508/G542X, one compound heterozygote
for ∆F508/3849+10kbC-T, five heterozygote for ∆F508,
one G551D/WT, one R117H/WT, one homozygote for
621+1G-T, and one girl with 5T/7T alleles in intron 8 (to-
tal of 18% with mutations).
Twenty-two percent of the adults in group 1) had CFTR
mutations, namely two ∆F508/∆F508, thirteen ∆F508/
WT, one compound for R117H/WT and 1466delAATT
(frameshift mutation in exon 9), one R117H/G542X, one
G551D/WT, one 3849+10kb C-T/WT, one compound
heterozygote for ∆F508/1248+1 A → G (splice mutation
in intron 7), and two individuals with ∆F508/3849+10kb
C-T. Table 2) gives the details for these individuals. Specif-
ics for persons with no identified mutation albeit clinical
indications for CF are not shown because of space limita-
tions. They comprise 133 individuals, 54 of these were an-
alysed for 16 mutations, 79 for 29 mutations of which 13
were examined further with DGGE and sequencing of sus-
picious fragments (a detailed documentation is available
upon request). Virtually none of these developed CF as
confirmed by our referring clinicians [22].
Group 2) consisted of 12 women (all WT/WT and 7T/7T
or 7T/9T) and 20 men. Nine of these men (45%) had nor-
mal alleles (and a benign thymidine polymorphism in in-
tron 8) at the loci analysed, seven men had a genotype of
5T/9T with ∆F508/WT, one showed 7T/9T with ∆F508/
WT, one had 9T/9T with ∆F508/WT, and one had 7T/9T
with G542X/WT. As such, of the 20 male patients referred
to us because of infertility, 45% had the ∆F508 mutation
and 77% of those were additionally affected in intron 8 by
the 5T mutation (table 2). The women in this group (all
without clinical symptoms and normal genotype) sup-
posedly have the normal population risk of being a CF
carrier. Consequently, they are arranged in the separate
category 2b.
Of 54 individuals in group 3, tested because their partners
or relatives had CFTR mutations, 37% had mutated alle-
les: seventeen persons had the genotype ∆F508/WT, one
had G551D/WT, one had 3849+10kb C-T, and one per-
son had G542X/WT (table 2).
In total, the ∆F508 mutation represented 83% (57 of 68)
of all exon mutations in this cohort (table 2). The ∆F508
mutation has a strong association with the 9T allele on the
same chromosome. This can be inferred because all ten
∆F508 homozygotes had 9T/9T alleles, and 37 of 38
∆F508 heterozygotes had at least one 9T allele. On the
other hand, only 25 out of 188 WT/WT genotypes had a
7T/9T, four had a 9T/9T polymorphism, but 157 WT/WT
genotypes were associated with a 7T/7T polymorphism.
This association of ∆F508 and 9T has been observed be-
fore [13]. Eight 5T alleles of a total of fifteen were found
in individuals other then the men with fertility problems
referred from IVF clinics.
Of all 257 persons analysed for CF mutations, 105 were
examined only for 16 mutations (Roche assay), 152 for 29
mutations (Roche + Innogenetics assay), 31 individuals
were tested further by DGGE of all exons and sequencing
of suspicious fragments. Of the 71 CFTR mutations, 69
were found merely by the assay with 16 mutations (n =
257), none was found additionally with the second re-
verse line probe (n = 152), and 2 mutations were found by
DGGE and sequencing (n = 31). Evaluation of our results
by contacting the referring clinicians attested good per-
formance of our assays: Virtually all patients with CF were
found, whereas probands without mutations (by our
tests) did not develop CF later on [22].
In comparison to CF mutation-frequencies in some Euro-
pean countries, the CF alleles we found (>2%) with our
tests show the following distribution in our cohort:
∆F508: 83% (Romania:27%, Switzerland: 43%, Den-
mark: 87,2% [19]); G542X: 4,4% (France: 3,1%, Italy:
4,8%, Spain: 7,7%); G551D: 4,4% (UK: 3,1%, Czechia:
4,0%, Ireland: 6,9%), 3849+10kbC-T: 2,9% (Germany:
1,2%, Poland: 2,6%, Latvia: 12,5%), R117H: 2,9%
(Greece: 1,2%, Ireland: 2,0%, Norway: 3,0%)
Because we participate in the European Quality assess-
ment trial for Cystic Fibrosis, we could evaluate the qual-
ity of the Roche Amplicor CF test in this regard as well. In
the case of the G551D/WT R553X/WT genotype, the Ro-
che test needs careful interpretation (and ought to be im-
proved) because the hybridisation at the one locus
destabilised the hybridisation at the other locus which is
only 4 bp apart. Accordingly, the line assay showed a
G551D/G551D and R553X/R553X (two homozygote mu-
tations) genotype instead of the correct G551D/WT and
R553X/WT (compound heterozygote) genotype. The phe-BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
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notypic classification for such patient samples (full CF),
however, was accurate, all other samples were typed cor-
rectly. This limitation is not unique to the Roche CF assay
and is a characteristic of all mutation-specific assays in
that sequence variations near the interrogated mutation
affect test accuracy.
Discussion
Since the discovery of the cystic fibrosis transmembrane
conductance regulator (CFTR) gene [14–16] the number
of identified CF mutations has increased enormously. The
mutations can be classified according to their influence of
CFTR-mediated chloride secretion [17]. Mutations of cat-
egory I, II, and III lead to complete loss of gene function
(associated with pancreatic insufficiency), whereas class
IV and V mutations confer altered conductance properties
or reduced synthesis of the CFTR protein. Such reduced
synthesis caused by varying degrees of exon 9 splicing
have been found associated with three length variants
within the splice acceptor site in intron 8 [18].
Numerous methods for analysing CFTR mutations are
available, the number of mutations that should be tested
for routine diagnostic purposes still being a question of
debate. It may be best to have a two-tiered approach for
mutation detection, with an economical first step and fur-
ther more elaborate techniques for identifying rare muta-
tions [19]. Because we perform the "economical first step"
in our laboratory routinely, up to 29 of the most common
CFTR mutations were analysed with line probe assays.
Persons to be tested for CF mutations are referred to our
laboratory because of 1) symptoms typical for/indicative
of CF, 2) fertility problems, and 3) CF in relatives/part-
ners. This classification was kept for ease of presentation.
Because of financial and personnel restrictions, it is not
possible in our laboratory to analyse all specimen by
DGGE [20] and sequencing. Thus, reverse line probe as-
says are used as a first step analysis tool. From DNA extrac-
tion to the results the turnaround time is approximately 6
hrs. Both assays used are not automated and thus require
various manual steps. But the ease with which 30 muta-
tions and, very importantly, the thymidine polymor-
phism/mutation in intron 8 can be tested, make these
tests adept as a diagnosis tool for CF in the clinical labo-
ratory. Certainly, these tests were developed for the US
and Europe and cannot be adapted for other ethnic
groups. In summary, the frequency of CF chromosomes in
the cohort examined with our tests was 26%, with the
∆F508 allele affecting 83% of the CF chromosomes. This
is considerably higher than the proportion of ∆F508 alle-
les of 55% found in a previous study in southern Austria
[21]. Five other mutations in CF chromosomes were
found with these tests, four of which with a frequency
above 2%. The only other mutations detected by sequenc-
ing, were a splice site mutation in intron 7 (1248+1 A-G)
and a frame shift mutation in exon 9 (1466delAATT).
Austrian law requires genetic counselling for persons seek-
ing genetic diagnosis. In this context, careful explanation
of positive and negative test results must be given. Where-
as the meaning of a positive test result would yield clear
conclusions, a negative result does not exclude possible
mutations at loci not examined by the test used. As more
than 800 putative mutations in the CFTR gene are known,
this has to be explained thoroughly to the patients seeking
advice.
The phenotype/genotype correlation in our cohort was
rather moderate: In the group of individuals referred to us
because of symptoms indicative for CF, mutations were
found in only 22% of the samples. However, our test sys-
tem is not inappropriate, as we have found practically all
patients with CF, whereas probands without mutations
did not develop clinical signs of CF later on [22]. Thus, the
increasingly pressing need for fast clinical reports was met
by our tests. Even slight indications for putative disease
must be analysed for their possible significance, nowa-
days, explaining the high number of samples with no mu-
tations found.
Somewhat higher results (37%) were found for individu-
als referred to us for genotype determination because their
partners/relatives had known CF mutations. Thirty sam-
ples with a WT/WT genotype by the reverse line blot assays
were analysed subsequently by DGGE and sequencing
that resulted in only two further determinations of the
mutant genotype. In both groups, the assays did not nec-
essarily depict unknown mutations, but the panel of the
commonest CF mutations was determined with certainty.
Very informative, though, were the results for the patients
referred from in vitro fertility clinics. For more than half
of the afflicted males, a conclusive analysis could be of-
fered by the tests, and the exclusion of the most common
mutations in their female partners was of utmost impor-
tance for their family planning. In this context, the deter-
mination of the 5T mutation in intron 8 was very
significant. With the wealth of information now available,
the association of the 5T mutation with fertility problems
is evident. The 5T polymorphism is considered now to be
a mutation with incomplete penetrance [12]. The dimin-
ished amount of CFTR gene product generated by the
splicing defect in intron 8 no longer sustains the physio-
logical functions required.
Conclusions
Our results show that current techniques allow a routine
first-line analyses of the CFTR gene status. It is a substan-
tial improvement for routine diagnostics to have availableBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/4
Page 8 of 8
(page number not for citation purposes)
a test system for 30 mutations plus the polypyrimidine
length variants in intron 8. Certainly. further develop-
ments will advance the diagnostic possibilities for CF con-
siderably. In this regard, it will be interesting to review our
samples with the new generation line probe assays that are
being developed, allowing a survey of up to 60 mutations
[23].
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